Cargando…

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

Breast Cancer (BC) is the second most common type of cancer worldwide and displays the highest cancer-related mortality among women worldwide. Targeted therapies have revolutionized the way BC has been treated in recent decades, improving the life expectancies of millions of women. Among the differe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sobhani, Navid, D’Angelo, Alberto, Pittacolo, Matteo, Roviello, Giandomenico, Miccoli, Anna, Corona, Silvia Paola, Bernocchi, Ottavia, Generali, Daniele, Otto, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523967/ https://www.ncbi.nlm.nih.gov/pubmed/30959874 http://dx.doi.org/10.3390/cells8040321

Ejemplares similares

Advances in anti-BRAF therapies for lung cancer
por: Roviello, Giandomenico, et al.
Publicado: (2021)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis
por: Sobhani, Navid, et al.
Publicado: (2021)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
por: Bernocchi, Ottavia, et al.
Publicado: (2021)

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer
por: Roviello, Giandomenico, et al.
Publicado: (2017)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Isolated Testicular Metastasis from Prostate Cancer
por: Bonetta, Alberto, et al.
Publicado: (2017)

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
por: Sobhani, Navid, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
por: Ianza, Anna, et al.
Publicado: (2021)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Mutant p53 as an Antigen in Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2020)

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
por: D’Angelo, Alberto, et al.
Publicado: (2020)

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2022)

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
por: Schettini, Francesco, et al.
Publicado: (2020)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2020)

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Second line of treatment for HER2-positive gastric cancer: an evolving issue
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2020)

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2022)

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma
por: Bonetta, Alberto, et al.
Publicado: (2017)

Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer
por: Sobhani, Navid, et al.
Publicado: (2020)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
por: Sobhani, Navid, et al.
Publicado: (2020)

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials
por: Roviello, Giandomenico, et al.
Publicado: (2016)

Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use
por: Cwalinski, Tomasz, et al.
Publicado: (2020)

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer
por: Milani, Manuela, et al.
Publicado: (2017)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6u2uop2fh1puic0geu0c2cptat